Winning
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good to see patent progression.
Its a small company that just seems to be constantly progressing. Its canadian pps is .065 right now. I would anticipate continued progress for the 4th quarter. It's snowballing right now. Its integrating into everything. Google, Drop Box, etc. Its not going to stop.
I'm currently getting my ass handed to me in my other plays. I want to add more of this stock. If anything it'll be flat and could work as a safety hedge in todays crazy ass market. My goal is accumulate into this for the remainder of 2018. I think 2019 is going to be a game changer.
Moovly launches powerful new WordPress Plugin
Moovly Plugin
Investor Video for 2018
video
Settling in at .07. Testing the bottom
Moovly moves one step closer into buyout territory with google integration
MOOVLY FULLY INTEGRATES INTO GOOGLE'S GSUITE
As a result of exceptional user demand, Moovly Media Inc. has launched two new Google integrations: full GDrive integration and an advanced YouTube publishing integration.
Moovly has experienced strong growth in the number of Moovly videos being published to social media. YouTube publishing is especially strong with almost 1,000 Moovly videos posted per day, a number which is growing quickly. Moovly's advanced integration into YouTube allows Moovly to add enhanced features to further enhance the user experience.
Integration with Google GSuite's GDrive (with its one billion registered users), allows Moovly users to import their own content directly from GDrive into the Moovly Studio Editor, making the publishing of their video content to YouTube extremely intuitive and efficient.
Brendon Grunewald, co-founder and chief executive officer of Moovly, stated: "Moovly is dedicated to responding quickly to user needs and providing the most advanced, easy-to-use video creation products available anywhere. The steady increase in Moovly clients making videos for YouTube and other social media made this enhanced integration an obvious strategic choice for us. GDrive integration saves our users time while allowing them to make use of their own creative assets. Moovly will continue to add partnerships and integrations to our platform as a way of better serving our loyal and growing customer base."
VERSUS SYSTEMS INC. SIGNS HAN CHOLO AS PRIZING PARTNER FOR THEIR PRIZE-BASED VIDEO GAME PLATFORM
Vancouver, British Columbia – September 22, 2016 – Versus Systems Inc. (the “Company” or
“Versus”) (CSE: VS) (Frankfurt: BMVA) has signed an agreement with leading lifestyle
brand Han Cholo to provide prizes for players and spectators participating in Versus-enabled
video games. This prizing partnership will provide video game developers and publishers the
ability to offer their players unique prizes, jewelry, and accessories for participating in
competitive matches of their games.
Han Cholo is the creator of “it” accessories for fashionistas, celebrities, and gamers alike – fans
include Kendrick Lamar, Brad Pitt, Miley Cyrus, the Yeah Yeah Yeahs, Snoop Dogg, and Daft
Punk. Founder and CEO Brandon Schoolhouse has developed accessories for Star Wars, Xbox,
Metal Gear Solid, Sonic the Hedgehog, and recently made a Voltron ring that was featured in the
movie Deadpool.
Brandon Schoolhouse said of Han Cholo joining Versus: “I’m really excited to be part of this
team. As a gamer, I know that this will change the gaming community as well as the world of
how we play games, bringing out the best in people. Competitive gaming just got a lot more
interesting. ‘GAME ON.’”
HAN CHOLO
Patent process moving forward for Dr. Markus' ELECTRONIC MEDICAL DEVICES AND METHODS.
"The present disclosure provides an elastic electronic circuit adapted to provide three dimensional elasticity while conforming to the curved or angled structures of a swellable medical device, such as a hydrogel or silicone hydrogel contact lens. The elastic electronic circuit can include a first pattern for flexibility in a first dimension, a second pattern for flexibility in a second dimension, and a third pattern for flexibility in a third dimension. Alternatively, the elastic circuit can include a first pattern for flexibility in a first dimension and a second pattern for flexibility in a second dimension. The resulting three-dimensional elasticity enables the use of electronic circuits on soft contact lenses, where manufacture and use will cause the lenses and circuits to swell and shrink. Furthermore, the electronic circuit will not distort the vision correction of the contact lens or otherwise cause discomfort or other negative side effects."
This will enable elastic circuits to be implemented into silicon hydrogels.
Versus Systems Partners with White Castle!
Versus Systems, Inc. Partners with White Castle® to introducelocation-targeted rewards on the WINFINITE gaming platform
White Castle – America’s first fast-food hamburger chain – to expand Versus’ in-game prize
offerings for video gamers and utilize the WINFINITE platform’s location-targeted
geofencing feature.
LOS ANGELES, August 14, 2018 - Versus Systems, Inc. (“Versus”) (CSE:VS) (OTCQB:VRSSF)
(FRANKFURT:BMVA) today announced it has partnered with White Castle, America’s first fast-food
hamburger chain, to use the WINFINITE platform to offer fans the chance to win White Castle products as prizes. Video game publishers and developers will now be able to use WINFINITE’s new location targeting feature to offer the prizes for in-game achievements based on the player’s proximity to certain White Castle locations. The first test of the prizing partnership will provide players with the ability to win rewards from select White Castle locations in the Louisville, Kentucky metropolitan area.
The partnership started today in 704 Games’ NASCAR Heat Mobile, with a free three (3) Piece Cheese Sticks offer for players in the Louisville metro market, including stores in Kentucky and Indiana, where the program will run through Sunday, August 26, 2018.
“Versus is excited to work with White Castle and for their team to be the first to use our local geofencing feature that allows players to win rewards at specific White Castle locations,” said Matthew Pierce, CEO of Versus Systems. “White Castle offering real world rewards to players based on their location and their in-game performance is a real advancement in gaming, and it unlocks a new level of relevance and convenience for players - showcasing the power of the WINFINTE platform.”
WHITE CASTLE
FDA approves Annovera! Trade is halted! Gonna be huge with this new female contraceptive!
Javon Frazier must to be creating some opportunities for Versus this summer. I think by Fall we will see the fruits of his hiring. He's just too good not to be. Going to use this quiet time to start acquiring. Been seeing some bursts in volume. I think something is up.
Versus Systems Appoints Javon Frazier (Studio71, Marvel Entertainment) to its Advisory Board
VANCOUVER, British Columbia, July 11, 2018 (GLOBE NEWSWIRE) -- Versus Systems, Inc. (“Versus”) (CSE:VS) (OTCQB:VRSSF) (FRANKFURT:BMVA) has announced the appointment of seasoned media executive Javon Frazier to its Advisory Board. As a member of the Advisory Board, he will provide strategic, financial, and tactical insights on gaming, media, influencer marketing, and branding.
Frazier currently serves as the Executive Vice President of Business Development and Strategy at Studio 71, a leading digital media company owned by the ProSiebenSat.1 Group, where he oversees strategic business development for influencer brands. Frazier is an accomplished executive with a proven track record in the global media landscape with experience in all areas of media and entertainment, including film, television, digital media, publishing and gaming.
Mr. Frazier has built several multi-million dollar brands over the past few years, including a card game called Joking Hazard, the Guava Juice toy subscription box, and most recently The Binding of Isaac: Four Souls table top game. His core competence lies in driving transactional revenue with new product launches, especially mobile games.
Prior to joining Studio71, he worked at Marvel for close to a decade, starting in business development with the studio's publishing and theatrical divisions. Here he helped launch Iron Man and The Incredible Hulk, before rapidly moving on to the Marvel's television arm as its Marketing Director, overseeing popular animated television series including Avengers: Earth’s Mightiest Heroes, Iron Man: Armored Adventures and Super Hero Squad.
Versus Systems Appoints Javon Frazier
Partnered up with Versus Systems. Gonna be a great partnership for all involved.
Partnered up with Moovly Media. It will be a great partnership and gamers will love the editing software.
Looks like its given back all of it's gains. Time to start adding again.
With the dollar being strong against the canadian dollar, Moovly looks to be a great bargain right now. Can get it for around 6-7 cents US. Company is strong and gaining steam. looking forward to the next quarterly.
Looks like we may seeing .40 CAN soon.
tell us diluted it will be
Well, so far Google and everybody else has failed at it. The point is, InWith has the technology right now. Any tech to come along that somehow finds a way around it is years away, if at all. As for the elastic circuit patent, it has enough in it to own the market on being able to mass produce silicon hydrogel contact lenses that have embedded circuitry.
Then you look at the details of InWith's 3 other patents and the plethora of those in the process of being reviewed, with 1st to file' status, its going to be an interesting path forward.
After personally talking with Silicon Valley patent lawyer heavyweights, WSGR, they are extremely excited about InWith's patent portfolio. Especially, the elastic circuit patent. The hour or so that I got to sit down with them and hear whats going on in the industry, who wants to be a player, etc, that pretty much puts to rest any skepticism I had or hear from those that aren't on the same level as the industry professionals that are actually working in this field.
Everything known to man, when it comes to technology, has a question mark around it. InWith has plenty as does every single company out there. The cards with this company will fall where they fall. Same with J&J, Samsung, Google, and the plethora of small companies out there trying nudge their way into this arena of smart contact lenses. Its going to be an exciting industry to follow.
InWith has stated their first prototype, built with a specific function for a specific biotech, is due to be complete this year. Will be interesting to learn what the function will be and with whom. If its a success, then they can start the clock, 2 years'ish, for the time to conduct trials, etc, to get the product to market.
If they want to do any kind of smart contact lens, they will have to work around InWith's elastic circuit patent. No point in having the lens if they can't manufacture it, so unless they plan on doing it on a lens other than silicon hydrogel, they will be paying InWith royalties.
650 of them are stoked!
I was at that meeting and what a great meeting it was!!!
You got me. Lol
The door is now open for new partnerships and sponsors. Its safe to say we are at the bottom. I am optimistically expecting positive developments on a monthly basis now.
Chimerix to present Phase 1 data for CMX521 at the 31st annual ISAR, The International Conference on Antiviral Research June 11th-June 15th 2018.
Q1 CC
"Details of the discovery and preclinical development of CMX521 will be presented next month at the International Conference on Antiviral Research. Our ongoing Phase 1 studies are designed to evaluate the pharmacokinetics, safety and tolerability of this novel nucleoside. Data from Phase 1 will allow us to choose optimize dosing regimens to take into Phase 2 efficacy studies in 2019."
"In late 2017, we initiated our first time in human study of CMX521, a nucleoside analog identified from our chemical library as a potential treatment and/or prevention for norovirus. We see this as a great commercial opportunity, as there are currently no approved therapies for the treatment of chronic norovirus infection or for use as a prevention strategy to limit the spread of an outbreak."………….
"Norovirus represents a large and costly unmet need. Each year, there are over 700 million cases resulting in 219,000 deaths. There’s also a significant economic toll, as the cost associated with norovirus is over $60 billion a year. And it’s not just a cruise ship virus, as it frequently impacts long-term care facilities and hospitals, causing ward shutdowns and infections among patients and health care providers.
Approaching the different prevention market segments will include looking at a number of important variables depending upon the setting. For example, in a norovirus outbreak, where there’s central area of control, such as in military facilities, hospitals or medical care settings, a protocol for use can be put in place to quickly disseminate an antiviral for preventing the further spread of this highly contagious virus.
We’ve already done exploratory market research with long-term care facilities, who are very interested in the CMX521 product profile, indicating that the product could have utility not only for preventing infection in patients, but also protecting staff."
Chimerix to Address Congressional Subcommittee in Support of Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA)
Address Congressional Subcommittee
DURHAM, N.C., June 05, 2018 (GLOBE NEWSWIRE) -- Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, announced that President and Chief Executive Officer M. Michelle Berrey, MD, MPH will deliver remarks before the House Committee on Energy and Commerce Subcommittee on Health at the hearing titled “Examining the Reauthorization of the Pandemic and All-Hazards Preparedness Act” at 10 a.m. ET on Wednesday, June 6 in Washington, D.C.
The purpose of the hearing is to reauthorize certain programs under the Pandemic and All-Hazards Preparedness Act (PAHPA), which originally passed in 2006 and seeks to improve the United States’ public health and medical preparedness and response capabilities for emergencies, whether deliberate, accidental or natural. The draft reauthorization legislation would increase funding for the Biomedical Advanced Research and Development Authority (BARDA) and the Project BioShield Special Reserve Fund, a secure funding source for the purchase and stockpile of critical medical countermeasures such as vaccines, therapeutics and diagnostics.
“Unfortunately, the threat of a biological event impacting the United States has never been more real,” said Dr. Berrey. “Our private-public partnerships over the last 15 years, particularly with BARDA, have been critical to the survival and progression of our smallpox program with brincidofovir. We commend the Committee for bipartisan collaboration on the PAHPA reauthorization. Companies like ours rely on the existence of a government market for medical countermeasures to sustain the long-term investment of researching and developing these therapies, which provide a critical bulwark against biological threats.”……………...
What new FDA designation means for Durham's Chimerix
Durham-based biopharma Chimerix (Nasdaq: CMRX) has banked a new designation from the U.S. Food and Drug Administration.
The FDA granted Chimerix Orphan Drug Designation for its lead drug candidate brincidofovir – known as brinci – for the treatment of smallpox. Benefits of the designation include the likes of development incentives and tax credits.
While members of the Chimerix team were traveling and unavailable for interviews, a company representative said the significance of the designation is two-fold.
“First, it underscores the critical need for the research and development of lifesaving medical countermeasures in the event of a smallpox outbreak, whether naturally occurring or the result of a bioterror event,” the representative noted. “Second, it provides many benefits, including a waiver of the FDA Prescription Drug User Fee Act.”…………………...
FDA designation
Chimerix Receives Orphan Drug Designation from the FDA for Brincidofovir for the Treatment of Smallpox
Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for brincidofovir for the treatment of smallpox.
Chimerix has been working with the Biomedical Advanced Research and Development Authority (BARDA) since 2011 to develop brincidofovir as a medical countermeasure for smallpox, demonstrating improved survival rates following confirmed orthopoxvirus infections in multiple animal models.
“We are very pleased to have received Orphan Drug Designation from the FDA for brincidofovir as a treatment for smallpox,” said M. Michelle Berrey, MD, MPH, President and Chief Executive Officer of Chimerix. “Though declared eradicated in the late 1970s, smallpox, whether natural or synthetic, continues to be a potential global threat in today’s interconnected world. We are committed to completing the development program for brincidofovir as a much-needed treatment option for smallpox, in close collaboration with BARDA and FDA.”
Orphan Drug Designation
Looking good from here!
New Video out
WINFINITE by Versus Systems
Versus Systems Officially Launches New Integrated Consumer Platform for Video Games and Esports: WINFINITE™
WINFINITE Seamlessly Integrates Into Mobile, PC, and Console Games to Create & Manage Competitions, Rewards and Prizes
Versus Systems and 704Games Launch WINFINITE Platform in NASCAR® Heat Mobile
June 07, 2018 12:15 PM Eastern Daylight Time
LOS ANGELES--(BUSINESS WIRE)--Versus Systems, Inc. (CSE: VS) (CSE: VS.CN) (OTCQB: VRSSF) (FRANKFURT: BMVA), a leading developer of brand engagement technology, today announced the official release of its new integrated consumer platform for gaming, WINFINITE™. The new platform will provide game publishers and developers the ability to easily integrate advanced player engagement technology and utilize Versus System’s expertise in prize-based contest and sweepstakes regulations to set up hassle-free in-game competitions and achievements for their players.
“WINFINITE leverages Versus Systems’ deep expertise in connecting brands with consumers in highly engaging ways”
Tweet this
With WINFINITE, game developers can now offer a wide-variety of prizes, including both in-game and real-world items, attaching those prizes to in-game competitions, milestones, or other achievements of the publisher’s choosing. Game developers, publishers and fans can learn more about the WINFINITE platform’s unique features by checking out a new video on Versus Systems official YouTube channel at
Great news! It was due! Only north from here. I expect them to be signing on more sponsors and partners soon. Its a complete no-brainer for any company that wants to to capture the gaming demographic.
Everybody's version of reality is different. I have my version of reality based on info that I know, and you base yours on what you know. Everything I've experienced thus far with Broadridge and my InWith shares has been positive. Looking forward to the next two years.
Bye